Vimarsana
Biggest News Aggregation in the World

John Jussup News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Jussup. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Jussup Today - Breaking & Trending Today

Shepherds' Taste for Hope raises $330K-plus to help end chronic homelessness – Ottawa Business Journal - Vimarsana News

Shepherds' Taste for Hope raises $330K-plus to help end chronic homelessness – Ottawa Business Journal

There is no top secret recipe behind the success of Taste for Hope. All that’s required is a handful of ingredients: benevolent chefs, generous sponsors, community-minded business leaders and hungry foodies working together toward the shared goal of reducing chronic homelessness. Already an Insider? Log in Get Instant Access to This Article Become an Ottawa Business Journal Insider and get immediate access to all of our Insider-only content and much more. Learn More and Become an Insider Critical Ottawa business news and analysis upda...

Source: obj.ca
Mike McCann Charity Golf Tournament hosted by CLV Group, InterRent raises more than $1.6M – Ottawa Business Journal - Vimarsana News

Mike McCann Charity Golf Tournament hosted by CLV Group, InterRent raises more than $1.6M – Ottawa Business Journal

The Mike McCann Charity Golf Tournament, presented by CLV Group and InterRent REIT, has topped itself again.

Source: obj.ca
Ottawa-based life sciences startup lands US$11.5M in fresh equity to fund cutting-edge cancer drugs - Vimarsana News

Ottawa-based life sciences startup lands US$11.5M in fresh equity to fund cutting-edge cancer drugs

An Ottawa-based startup working on treatments that use the body’s immune system to target cancer, COVID-19 and other diseases has landed millions of dollars in financing to ratchet up its research efforts. Orion Biotechnology’s new series-A round worth US$11.5 million is being led by Keiretsu Forum, a global syndicate of angel investors headquartered in San Francisco.  The new funding will help the firm expand its clinical trials of drug candidates produced by its proprietary platform that targets G-protein coupled receptors, or GPCRs, which play a key role in diseases such as cancer, HI...

Source: obj.ca